Effects of Brain Gangliosides on Functional Recovery in Experimental Regeneration and Reinnervation

Ceccarelli, B; Aporti, F.; Finesso, M.

doi:10.1007/978-1-4614-4614-9_17

Cited by 131 publications

(43 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, it facilitates neurite outgrowth (13)(14)(15), reduces neural degeneration (16 -19), and modulates protein kinase activity in injured brain tissue (20). GM1 also enhances NGF-induced tyrosine receptor kinase (Trk)A autophosphorylation (21).…”

mentioning

confidence: 99%

Orally Active Neurotrophin-Enhancing Agent Protects Against Dysfunctions of the Peripheral Nerves in Hyperglycemic Animals

Kakinoki¹,

Sekimoto²,

Yuki³

et al. 2006

Diabetes

View full text Add to dashboard Cite

Biological substances with neurotrophic activities, such as nerve growth factor (NGF) and monosialoganglioside GM1, have been considered as agents for diabetic peripheral neuropathy. Because recent studies have suggested that decreased availability of these substances might contribute to the pathogenesis of diabetic peripheral neuropathy, some clinical trials of NGF for diabetic peripheral neuropathy have been conducted and have led to mixed conclusions. The major reasons were its limited delivery to the nervous system and adverse effects induced by subcutaneous injection, which was necessary because NGF is a polypeptide. The current study investigates whether an orally active sialic acid derivative, MCC-257, has neuroprotective properties in diabetic peripheral nerves. MCC-257 augmented NGF activity in cultured dorsal root ganglia and PC12 (pheochromocytoma 12) cells. Treatment with MCC-257 elevated NGF levels in the sciatic nerve, accompanied by improvement in nerve conduction velocity in strepotozotocin-induced diabetic animals. More importantly, MCC-257 ameliorated small fiber dysfunctions, including thermal hypoalgesia, substance P content, and histopthological innervation in the plantar skin of diabetic animals. Thus, the orally active neurotrophin enhancer provides a new option for the clinical treatment of diabetic peripheral neuropathy. Diabetes 55:616 -621, 2006

show abstract

mentioning

confidence: 99%

Orally Active Neurotrophin-Enhancing Agent Protects Against Dysfunctions of the Peripheral Nerves in Hyperglycemic Animals

Kakinoki¹,

Sekimoto²,

Yuki³

et al. 2006

Diabetes

View full text Add to dashboard Cite

show abstract

“…1995). There are reports that in vivo exogenous gangliosides enhance regeneration of damaged peripheral nerve (Ceccarelli et al, 1975), spinal cord (Geisler et al, 1991), and brain (Sabel et al, 1988;Skaper et al, 1989;Sehengrund, 1990).…”

mentioning

confidence: 99%

Ganglioside GM1 Enhances Induction by Nerve Growth Factor of a Putative Dimer of TrkA

Farooqui¹,

Franklin²,

Pearl

et al. 1997

Journal of Neurochemistry

104

View full text Add to dashboard Cite

GM1 enhances nerve growth factor (NGF)-stimulated neuritogenesis and prevents apoptotic death of PC12 cells; both may be due to enhancement of TrkA dimerization. In this study, we examined the effect of GM1 on NGF-induced TrkA dimerization in Trk-PC12 (6-24) cells. NGF increased tyrosine phosphorylation of the 140-kDa protein (TrkA monomer), and preincubation with GM1 potentiated this effect. Adding the protein crosslinker bis(sulfosuccinimidyl) suberate with NGF resulted in the appearance of two major bands (220 and 330 kDa) when probed with antibodies against TrkA or phosphotyrosine, and GM1 also enhanced this effect. We interpret the 330-kDa band as being a homodimer of TrkA. The identity of the 220-kDa band is still not certain but may consist of a posttranslationally modified form of TrkA. Our results suggest that GM1 is augmenting the effects of NGF on PC12 cells by enhancing the dimerization and activation of the TrkA receptor. Key Words: Gangliosides-Nerve growth factor-Nerve growth factor-induced receptor dimerization-PCi 2 cells-GM1.

show abstract

“…Furthermore, it has been reported that GSLs were absorbed orally (Schmelz et al, 1994). Therefore, GSLs or their catabolites are expected to be origins of new drugs, and developments have been performed in various fields (Ceccarelli et al, 1976;Vantini et al, 1988;Bradly, 1990).…”

Section: Introductionmentioning

confidence: 99%

Thirteen-Week Repeated Dose Toxicity of Rice Bran Glycosphingolipid in Wistar Hannover (Galas) Rats

Moto¹,

Okamura²,

Watanabe³

et al. 2004

J. Toxicol. Sci.

View full text Add to dashboard Cite

-Rice bran glycosphingolipid (RBGSL), one of the glycosphingolipids (GSLs), has been widely used as a food additive, a base of cosmetics, and so on. As a part of the safety assessment of RBGSL, a 13-week repeated dose toxicity study was performed in Wistar Hannover (GALAS) rats. Male and female rats were divided into 4 groups consisting of 8 animals and were given 0, 60, 250, and 1000 mg/kg BW of RBGSL orally 5 times weekly for 13 weeks. During the experiment, no deaths were observed in any groups, and there were no remarkable changes in general appearance, body weight, food and water consumption, hematological and serum biochemical parameters, organ weight and histopathological findings between the control and treated groups. On the basis of these data, the no-observedadverse effect level (NOAEL) of RBGSL in Wistar Hannover rats was considered to be 1000 mg/kg BW/ day or more.

show abstract

Effects of Brain Gangliosides on Functional Recovery in Experimental Regeneration and Reinnervation

Cited by 131 publications

References 19 publications

Orally Active Neurotrophin-Enhancing Agent Protects Against Dysfunctions of the Peripheral Nerves in Hyperglycemic Animals

Orally Active Neurotrophin-Enhancing Agent Protects Against Dysfunctions of the Peripheral Nerves in Hyperglycemic Animals

Ganglioside GM1 Enhances Induction by Nerve Growth Factor of a Putative Dimer of TrkA

Thirteen-Week Repeated Dose Toxicity of Rice Bran Glycosphingolipid in Wistar Hannover (Galas) Rats

Contact Info

Product

Resources

About